Compugen's three largest insider shareholders as of August 29, 2026 are David Silberman (Chief Financial Officer, 55.00K shares), Zurit Levine (Svp, Business Development, 47.38K shares), Russo Sharon Kredo (Svp, Research Discovery, 37.50K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David Silberman | Chief Financial Officer | 55,000 | 0 | 55,000 | 19.4% | 30 Jul, 2026 |
| 2 | Zurit Levine | Svp, Business Development | 47,375 | 0 | 47,375 | 16.8% | 30 Jul, 2026 |
| 3 | Russo Sharon Kredo | Svp, Research Discovery | 37,500 | 0 | 37,500 | 13.3% | 30 Jul, 2026 |
| 4 | Michelle Mahler | Chief Medical Officer | 36,625 | 0 | 36,625 | 13.0% | 30 Jul, 2026 |
| 5 | Savitzky Kinneret Livnat | Director | 20,850 | 0 | 20,850 | 7.4% | 30 Jul, 2026 |
| 6 | Sanford S Zweifach | Director | 20,180 | 0 | 20,180 | 7.1% | 30 Jul, 2026 |
| 7 | Gilead Halevy | Director | 18,907 | 0 | 18,907 | 6.7% | 30 Jul, 2026 |
| 8 | Eran Perry | Director | 17,500 | 0 | 17,500 | 6.2% | 30 Jul, 2026 |
| 9 | Mathias Hukkelhoven | Director | 17,500 | 0 | 17,500 | 6.2% | 30 Jul, 2026 |
| 10 | Eran Ophir | President And Ceo | 11,375 | 0 | 11,375 | 4.0% | 27 Apr, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 29 Jul, 2026 | Eran Perry | Director | Acquired A | 7,500 | $0.00 | $0 | 17,500 | Direct |
| 29 Jul, 2026 | Russo Sharon Kredo | Svp, Research Discovery | Acquired A | 18,000 | $0.00 | $0 | 37,500 | Direct |
| 29 Jul, 2026 | Gilead Halevy | Director | Acquired A | 7,500 | $0.00 | $0 | 18,907 | Direct |
| 29 Jul, 2026 | Zurit Levine | Svp, Business Development | Acquired A | 18,000 | $0.00 | $0 | 47,375 | Direct |
| 29 Jul, 2026 | Michelle Mahler | Chief Medical Officer | Acquired A | 13,500 | $0.00 | $0 | 36,625 | Direct |
| 29 Jul, 2026 | Eran Ophir | President And Ceo | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |
| 29 Jul, 2026 | Anat Cohen-Dayag | Director | Acquired A | 100,000 | $0.00 | $0 | 100,000 | Direct |
| 29 Jul, 2026 | Sanford S Zweifach | Director | Acquired A | 7,500 | $0.00 | $0 | 20,180 | Direct |
| 29 Jul, 2026 | Savitzky Kinneret Livnat | Director | Acquired A | 7,500 | $0.00 | $0 | 20,850 | Direct |
| 29 Jul, 2026 | Mathias Hukkelhoven | Director | Acquired A | 7,500 | $0.00 | $0 | 17,500 | Direct |
| 29 Jul, 2026 | Pierre Ferre | Chief Operating Officer | Acquired A | 70,000 | $0.00 | $0 | 70,000 | Direct |
| 29 Jul, 2026 | David Silberman | Chief Financial Officer | Acquired A | 19,500 | $0.00 | $0 | 55,000 | Direct |
| 29 Jul, 2026 | Mathias Hukkelhoven | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 29 Jul, 2026 | David Silberman | Chief Financial Officer | Acquired A | 26,000 | $0.00 | $0 | 26,000 | Direct |
| 29 Jul, 2026 | Michelle Mahler | Chief Medical Officer | Acquired A | 18,000 | $0.00 | $0 | 18,000 | Direct |
| 29 Jul, 2026 | Russo Sharon Kredo | Svp, Research Discovery | Acquired A | 24,000 | $0.00 | $0 | 24,000 | Direct |
| 29 Jul, 2026 | Sanford S Zweifach | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 29 Jul, 2026 | Eran Perry | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 29 Jul, 2026 | Zurit Levine | Svp, Business Development | Acquired A | 24,000 | $0.00 | $0 | 24,000 | Direct |
| 29 Jul, 2026 | Savitzky Kinneret Livnat | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |